Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Interim systemic lung cancer ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...

TRIANA Biomedicines Announces First Patient Dosed in a Phase 1/2 Trial Evaluating TRI-611 for the Treatment of ALK+ Non-small Cell Lung Cancer ...

Research shows tumor debulking in advanced colorectal cancer does not enhance survival outcomes and may increase adverse effects, questioning its efficacy.

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an abstract for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody ...

Imaging studies of more than 27,000 adults link a healthier thymus on CT scans with a longer life and lower risks of ...

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...

Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.

The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study ...

UPPSALA, SE / ACCESS Newswire / March 18, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based biomarkers for cancer treatment monitoring, today ...